What's New

Last Posted: Sep 28, 2023

• Emerging cancer risks in BRCA2 pathogenic germline variant carriers.
  Patrick R Benusiglio et al. Eur J Hum Genet 2023 9
• Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study).
  Karen Leroy et al. PLoS One 2023 18(9) e0291495
• Utility of multigene panel next-generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer.
  Udit Nindra et al. Intern Med J 2023
• Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Using a Real-World Database.
  Naleen Raj Bhandari et al. J Natl Compr Canc Netw 2023 21(9) 934-944.e1
• Clinical importance of the range of detectable variants between the Oncomine Dx target test and a conventional single-gene test for EGFR mutation.
  Tadashi Sakaguchi et al. Sci Rep 2023 13(1) 13759
• A Machine Learning-Based Model to Predict In-Hospital Mortality of Lung Cancer Patients: A Population-Based Study of 523,959 Cases.
  Que N N Tran et al. Adv Respir Med 2023 91(4) 310-323
• Machine learning strengthened prediction of tracheal, bronchus, and lung cancer deaths due to air pollution.
  Jagadish Kumar Mogaraju et al. Environ Sci Pollut Res Int 2023
• Predicting lung cancer survival based on clinical data using machine learning: A review.
  Fatimah Abdulazim Altuhaifa et al. Comput Biol Med 2023 165107338
• Germline EGFR mutations and familial lung cancer.
  Geoffrey R Oxnard et al. J Clin Oncol 2023 101200JCO2301372
• T790M detection rate after first-line combination therapy with bevacizumab and EGFR-TKIs in advanced NSCLC (TERRA Study).
  Chih-Hsi Scott Kuo et al. Am J Cancer Res 2023 13(7) 3100-3112
• Assessing a Polygenic Risk Score for Lung Cancer Susceptibility in Non-Hispanic White and Black Populations.
  Matthew R Trendowski et al. Cancer Epidemiol Biomarkers Prev 2023 8
• Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data.
  Jeffrey A Scott et al. JCO Oncol Pract 2023 OP2200611
• Genetic Profiles Affect Smokers' Lung Cancer Risk
  CN Martimez, Medscape, August 2023
• The Inflammatory Profile Correlates with COVID-19 Severity and Mortality in Cancer Patients
  CE Budin et al, JPM, August 7, 2023
• Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial.
  Miguel García-Pardo et al. JAMA Netw Open 2023 6(7) e2325332
• Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
  Parneet K Cheema et al. Curr Oncol 2023 30(7) 6473-6496
• Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory.
  Pratibha Bhai et al. Front Oncol 2023 131208244
• Importance of ROS1 gene fusions in non-small cell lung cancer.
  Meri Muminovic et al. Cancer Drug Resist 2023 6(2) 332-344
• Improving the turnaround time of molecular profiling for advanced non-small cell lung cancer: Outcome of a new algorithm integrating multiple approaches.
  G Treichler et al. Pathol Res Pract 2023 248154660
• Low-dose CT screening in relatives with a family history of lung cancer.
  Chi-Liang Wang et al. J Thorac Oncol 2023

More